Nabriva Therapeutics PLC represents a strong commitment to advancing the field of anti-infectives and improving patient outcomes. Their corporate philosophy revolves around innovation, scientific excellence, and dedication to bringing novel treatments to market. The company is focused on addressing the global challenge of antibiotic resistance by developing and commercializing innovative antibiotics. With a patient-centric approach, Nabriva Therapeutics PLC strives to meet unmet medical needs and provide effective solutions for serious infections. Through continuous research and development efforts, they aim to contribute to the fight against infectious diseases and improve the quality of life for patients worldwide.

Nabriva Therapeutics PLC is primarily present in the United States and Europe. The company focuses on developing innovative medications to treat serious infections. With its headquarters in Dublin, Ireland, Nabriva Therapeutics PLC has a strong presence in the European pharmaceutical market. In the United States, the company's operations center around promoting and commercializing their products to healthcare professionals and patients. Nabriva Therapeutics PLC aims to address the global need for effective antibiotics by expanding its reach and market presence.

Nabriva Therapeutics PLC has achieved several significant milestones. Firstly, the company successfully received approval from the U.S. Food and Drug Administration (FDA) for their novel antibiotic, lefamulin, designed to treat community-acquired bacterial pneumonia (CABP). This approval marked a major milestone for Nabriva Therapeutics PLC as lefamulin became the first and only systemic oral and IV treatment approved in nearly two decades for CABP patients. Additionally, the company has made progress in expanding lefamulin's availability in Europe, receiving marketing authorization in several countries. Nabriva Therapeutics PLC's achievements demonstrate their commitment to advancing innovative solutions for infectious diseases treatment.

Nabriva Therapeutics PLC is a pharmaceutical company headquartered in Dublin, Ireland. Established in 2005, Nabriva focuses on developing innovative treatments to combat serious infections. The company has a strong emphasis on research and has built a robust pipeline of potential antibiotics. Nabriva Therapeutics PLC aims to address the growing global issue of antibiotic resistance through its novel approaches. With a dedicated team of experts and strategic partnerships, Nabriva Therapeutics PLC strives to improve patient outcomes and contribute to the fight against infectious diseases.

The main competitors of Nabriva Therapeutics PLC in the market include biopharmaceutical companies such as Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc, and AstraZeneca plc. These companies are also actively involved in the development and commercialization of innovative therapeutics and solutions for various medical conditions. Nabriva Therapeutics PLC competes with these industry leaders by leveraging its unique approach, research and development pipeline, and commercialization strategies.

Nabriva Therapeutics PLC is primarily active in the pharmaceutical industry.

The business model of Nabriva Therapeutics PLC focuses on developing and commercializing innovative antibiotic treatments to address significant unmet medical needs. As a pharmaceutical company, Nabriva Therapeutics is dedicated to discovering, developing, and bringing to market novel antibiotics to combat serious infections caused by multi-drug resistant bacteria. By leveraging its expertise in antibiotics research and development, Nabriva Therapeutics aims to provide healthcare professionals with effective and safe treatment options for patients suffering from various bacterial infections. Through its continuous commitment to enhancing patient care, Nabriva Therapeutics strives to make a positive impact on global public health.

De Nabriva Therapeutics K/W is -0,02.

De Nabriva Therapeutics KUV is 0,01.

De AlleAktien Kwaliteitsscore voor Nabriva Therapeutics is 3/10.

De verwachte Nabriva Therapeutics omzet is 105,91 mln. USD.

De verwachte Nabriva Therapeutics winst is -63,80 mln. USD.

Nabriva Therapeutics PLC is a biopharmaceutical company specializing in the research, development, and commercialization of anti-infectives. The company's business model is based on providing innovative antibiotic products for the treatment of bacterial infections. They focus on developing and approving products specifically targeted against bacterial infectious diseases, including skin and soft tissue infections, outpatient respiratory tract infections, and nosocomial infections. Nabriva Therapeutics is committed to discovering and developing new and innovative therapies to meet the global demand for more effective antibiotics. The company has become a leading player in antibiotic development by conducting comprehensive drug research and development to address treatment gaps. Their three main products are Mavenclad, CONTEPO, and Lefamulin. Mavenclad is an oral Cladribine preparation for the treatment of relapsing multiple sclerosis (MS), representing a significant milestone in MS patient treatment. CONTEPO is an intravenous antibiotic for the treatment of complicated urinary tract infections, including pyelonephritis. It is the first antibiotic approved for treating infections caused by ESBL-producing Enterobacteriaceae, a growing global problem of antibiotic resistance. Lefamulin is an oral and intravenous antibiotic for the treatment of community-acquired bacterial pneumonia (CABP). It is the first antibiotic approved for CABP in the last 20 years. Nabriva Therapeutics operates a strong and extensive research and development program based on clinical studies to demonstrate the effectiveness and safety of their products. Additionally, they have a dynamic marketing program that collaborates closely with healthcare providers, clinicians, and patients to increase the availability and access to their products. The company distributes and markets its products in collaboration with a global list of partners, including a strategic partnership with Merck Sharp & Dohme Corp. (MSD) to drive the global introduction of Lefamulin. Overall, Nabriva Therapeutics has built a strong market position in the global anti-infective industry and has an excellent reputation in the field. They are positioned as a leader in the development and commercialization of antibacterial therapeutics, and with their strong research and development department and innovative products, they are on track to continue delivering successful antibiotic products to meet global demand.

Nabriva Therapeutics keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Nabriva Therapeutics of het bedrijf keert geen dividend uit.

De ISIN van Nabriva Therapeutics is IE00BL53QQ85.

Het WKN van Nabriva Therapeutics is A2QKWR.

De ticker van Nabriva Therapeutics is NBRV.

Binnen de laatste 12 maanden betaalde Nabriva Therapeutics een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Nabriva Therapeutics naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Nabriva Therapeutics is momenteel .

Nabriva Therapeutics betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Nabriva Therapeutics betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Nabriva Therapeutics wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Nabriva Therapeutics van 1-8-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 1-8-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 1-8-2024.

In het jaar 2023 heeft Nabriva Therapeutics 0 USD aan dividenden uitgekeerd.

De dividenden van Nabriva Therapeutics worden in USD uitgekeerd.